Mantle cell lymphoma is an uncommon type of blood cancer caused by excessive lymphocyte growth. Mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma that develops when tumors in the lymph nodes enter the bloodstream and spread to bone marrow, liver, digestive tract, spleen.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1148
Weight loss, Loss of appetite fever, vomiting, and nausea are all common symptoms of the disease. The type of treatment for a patient with mantle cell lymphoma is determined by several factors such as the patient’s age, stage of disease, and overall health. The U.S. Food and Drug Administration (FDA) authorized a supplemental new drug application for bortezomib (Velcade) in 2012, which upgrades the current label to allow subcutaneous administration for the mantle cell lymphoma (MCL) patients treatment having who have had at least one prior therapy.
During the forecast period, the rising incidence of mantle cell lymphoma is expected to fuel the global mantle cell lymphoma treatment market growth.
Increasing incidences of mantle cell lymphoma and growing research and development activities in the healthcare segment are major factors driving the global mantle cell lymphoma treatment market growth, leading to a potential product pipeline. According to a 2017 Drug Development Technology study, a projected 3,300 cases of mantle cell lymphoma are reported in the U.S. each year. With federal agency approval, the mantle cell lymphoma treatment market is expected to gain substantial traction. For instance, AstraZeneca received the U.S. FDA approval for Calquence in October 2017 through the U.S. FDA’s accelerated approval pathway for the treatment of adult patients with mantle cell lymphoma. Moreover, the discovery of targeted therapies with low toxicity profiles for the treating of relapsed mantle cell lymphoma in association with authorized therapies is a key factor driving the growth of the mantle cell lymphoma treatment market. However, drugs’ serious side effects such as neutropenia, diarrhea, and anemia are hindering the growth of the global mantle cell lymphoma treatment market.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1148
The U.S. Food & Drug Administration’s (FDA) accelerated approval pathway program is expected to boost the mantle cell lymphoma treatment market growth in North America.
Coherent Market Insights divides the global mantle cell lymphoma treatment market into five regions: Asia Pacific, Africa, Latin America, the Middle East, North America, and Europe. During the forecast period, North America is estimated to hold the largest share in the mantle cell lymphoma treatment market. This is due to the disease’s rising incidence rate in the region. According to the Leukemia and Lymphoma Society, around 70,800 new cases of non-Hodkin lymphoma were diagnosed in the U.S. in 2014, with mantle cell lymphoma accounting for about 6% (4,200) of the total cases. In addition, the U.S. FDA’s Center for Drug Evaluation and Research collaborates with manufacturers on developing drugs, approval, and the Breakthrough Therapy Destination Program, which aims to provide treatment affordable to patients having rare diseases. In 2013, the Food and drug administration approved Janssen Pharmaceuticals, Inc.’s Imbruvica (ibrutinib) as a breakthrough therapy destination for patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Due to increasing initiatives by the government and increased research and development in fighting the disease, the mantle cell lymphoma treatment market in the Asia Pacific region is expected to grow at a high rate during the forecast period.
Patients with refractory or relapsed mantle cell lymphoma have unmet needs, and key players are providing products that address those needs. Kite Pharma Inc., for instance, is focusing to develop engineered autologous T cell therapy products for cancer treatment. KTE-C19 was first tested in Phase 2 clinical trial in patients with refractory or relapsed mantle cell lymphoma in 2015.
Major players operating in the global mantle cell lymphoma treatment market are GlaxoSmithKline Plc, Abbvie, Inc, Johnson and Johnson, Eli Lilly and Company, Kite Pharma, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Amgen, Inc., F.Hoffman La Roche Ltd., Bayer AG, and Celgene Corporation.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/1148
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Mantle Cell Lymphoma Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Mantle Cell Lymphoma Treatment Industry Impact
Chapter 2 Global Mantle Cell Lymphoma Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Mantle Cell Lymphoma Treatment (Volume and Value) by Type
2.3 Global Mantle Cell Lymphoma Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Mantle Cell Lymphoma Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Mantle Cell Lymphoma Treatment Market Analysis
Chapter 6 East Asia Mantle Cell Lymphoma Treatment Market Analysis
Chapter 7 Europe Mantle Cell Lymphoma Treatment Market Analysis
Chapter 8 South Asia Mantle Cell Lymphoma Treatment Market Analysis
Chapter 9 Southeast Asia Mantle Cell Lymphoma Treatment Market Analysis
Chapter 10 Middle East Mantle Cell Lymphoma Treatment Market Analysis
Chapter 11 Africa Mantle Cell Lymphoma Treatment Market Analysis
Chapter 12 Oceania Mantle Cell Lymphoma Treatment Market Analysis
Chapter 13 South America Mantle Cell Lymphoma Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Mantle Cell Lymphoma Treatment Business
Chapter 15 Global Mantle Cell Lymphoma Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027